MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Retrophin Company Profile (NASDAQ:RTRX)

Consensus Ratings for Retrophin (NASDAQ:RTRX) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.67 (54.68% upside)

Analysts' Ratings History for Retrophin (NASDAQ:RTRX)
Show:
DateFirmActionRatingPrice TargetActions
6/27/2016Leerink SwannReiterated RatingBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016BMO Capital MarketsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016JMP SecuritiesReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/4/2015Deutsche BankBoost Price TargetBuy$52.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015NomuraReiterated RatingBuy$31.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2015Avondale PartnersInitiated CoverageOutperform$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Retrophin (NASDAQ:RTRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.50)($0.04)$17.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q3($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Retrophin (NASDAQ:RTRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.26)($0.26)($0.26)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)
Dividend History for Retrophin (NASDAQ:RTRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Retrophin (NASDAQ:RTRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Retrophin (NASDAQ:RTRX)
DateHeadline
06/27/16 10:21 AMRetrophin, Inc. (RTRX) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 06:50 PMAnavex's Lead Candidate Gets Orphan Drug Status Yet Again
06/23/16 08:52 AMRetrophin (RTRX) Data Shows RE-024 Safe and Well Tolerated with Clinically Meaningful Improvements - StreetInsider.com
06/23/16 08:52 AMRetrophin Inc. (RTRX) is Trading Higher on Unusual Volume for June 21 - Equities.com
06/22/16 10:55 AMRetrophin (RTRX) Is Today's Strong On High Volume Stock - TheStreet.com
06/21/16 03:51 PMInovio Stock Up, Zika Vaccine Gets Nod for Phase I Study -
06/21/16 10:32 AMFate's (FATE) ProTmune Gets Fast Track Status, Stock Up
06/21/16 10:32 AMRetrophin (RTRX) to Acquire Usodeoxycholic Acid Rights from Asklepion Pharma in ~$24M Deal
06/21/16 05:03 AMRETROPHIN, INC. Files SEC form 8-K, Other Events -
06/20/16 05:55 PMRetrophin (RTRX) to Acquire Usodeoxycholic Acid Rights from Asklepion Pharma in ~$24M Deal - StreetInsider.com
06/20/16 05:55 PMThis Weeks Broker Views For Retrophin, Inc. (RTRX) - Fiscal Standard
06/20/16 03:59 PMRetrophin Acquires Liquid Formulation of Ursodeoxycholic Acid - [at noodls] - June 20, 2016 SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid ...
06/13/16 09:09 AMAgios Reports Favorable Phase II PK Deficiency Study Data
06/11/16 09:07 AMJune 24 Deadline Upcoming in Settlement in the Retrophin Inc (NASDAQ:RTRX) Investor Lawsuit
06/08/16 06:44 PMRETROPHIN INC. (NASDAQ:RTRX) Financial Condition Compared to S&P 500 - CML News
06/08/16 09:14 AMEx-drug executive Shkreli pleads not guilty to latest charge
06/08/16 09:14 AMTeva's Pain Drug Vantrela Recommended for FDA Approval
06/06/16 04:44 PMFacing new conspiracy charge, Martin Shkreli pleads not guilty -
06/06/16 03:51 PMMartin Shkreli Earns Another Charge, Pleads Not Guilty - Martin Shkreli, co-founder of the hedge fund MSMB Capital Management, co-founder and former CEO of the biotechnology firm Retrophin Inc (NASDAQ: RTRX), and founder and former CEO of Turing Pharmaceuticals, was back in court on Monday. Shkreli -– dubbed by the media as “the most hated man in America” after acquiring notoriety for hiking the price of a drug used to ...Full story available on Benzinga.com
06/05/16 11:19 PM[$$] Martin Shkreli Faces a New Conspiracy Charge -
06/05/16 08:53 AMMartin Shkreli faces new conspiracy charge - Seeking Alpha
06/03/16 08:41 PMMore charges against ex-pharmaceutical executive Shkreli -
06/03/16 06:49 PM'A Potentially Transformative Event' For Retrophin
06/03/16 05:55 PMMartin Shkreli hit with new securities charge: report -
06/03/16 05:23 PMEx-drug executive Shkreli hid control of shares, U.S. says -
06/03/16 04:14 PMProsectors File New Charges Against Martin Shkreli -
06/03/16 03:55 PMU.S. Alleges Shkreli Hid Control of Retrophin Shares -
06/03/16 09:09 AMRetrophin Inc (RTRX) EVP Sells $155312.50 in Stock - Let Me Know About This
06/02/16 06:41 PM'A Potentially Transformative Event' For Retrophin - Benzinga - Benzinga'A Potentially Transformative Event' For RetrophinBenzingaNot often do you see sell-side firms throwing around weighty phrases such as "transformative event" for a specific company. However, JMP did just that in a note Thursday morning for Martin Shkreli's old company, Retrophin Inc RTRX 2.25%. Within the ...
06/02/16 09:18 AMAlexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status - Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Snapshot Report) , Retrophin, Inc. (RTRX - Snapshot Report) and Bristol-Myers Squibb Company (BMY - Analyst Report) . All three stocks sport a Zacks Rank #1 ...
06/01/16 09:09 AMTeva's Huntington Disease Drug Receives CRL from the FDA - Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Snapshot Report) , Retrophin, Inc. (RTRX - Snapshot Report) and Bristol-Myers Squibb Company (BMY - Analyst Report) . All three stocks sport a Zacks Rank #1 ...
06/01/16 09:09 AMIntegra (IART): Strong Revenue Growth on Global Prospects - Integra currently carries a Zacks Rank #3 (Hold). Key Sector Picks Some better-ranked stocks in the medical sector are Retrophin, Inc. RTRX, Neogenomics Inc. NEO and ANI Pharmaceuticals, Inc. ANIP. All the three stocks sport a Zacks Rank #1 (Strong Buy).
05/26/16 03:37 PMRetrophin to Present at Upcoming Investor Conferences - [at noodls] - May 26, 2016 SAN DIEGO, May 26, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the following upcoming investor conferences: ...
05/25/16 05:12 PMRetrophin, Inc. (NASDAQ:RTRX) Quarterly EPS From Continuing Operations Stands At $0.3071 - Investor Newswire - Retrophin, Inc. (NASDAQ:RTRX) Quarterly EPS From Continuing Operations Stands At $0.3071Investor NewswireRetrophin, Inc. (NASDAQ:RTRX) posted net basic EPS of $3.49 for the year ended 2016-03-31. For the quarter ended 2016-03-31, basic net EPS was $3.49. For the year ended 2016-03-31, basic shares outstanding count is 33.56 while for the quarter ended ...
05/25/16 03:02 PMRETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
05/25/16 08:27 AMAbbVie/Boehringer Report Crohn's Disease Drug Interim Data - and Retrophin, Inc. (RTRX - Snapshot Report) , each sporting a Zacks Rank #1 (Strong Buy). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> Get the ...
05/24/16 05:18 PMRetrophin, Inc. (NASDAQ:RTRX) One-Year Price Target At $24.67 - Investor Newswire - Retrophin, Inc. (NASDAQ:RTRX) One-Year Price Target At $24.67Investor NewswireFirst Call has set a 52-week price target of $24.67 on Retrophin, Inc. (NASDAQ:RTRX) stock after completion of its survey. For the approaching quarter, EPS estimate is set at $0.36 and for underway fiscal at $0.08. This estimate for next year is $-0.27 ...and more »
05/24/16 07:51 AMWill Retrophin (RTRX) Continue to Surge Higher? -
05/23/16 10:22 PMStock Paining Investors: Retrophin, Inc. (NASDAQ:RTRX) - Wall Street Hints and News - Stock Paining Investors: Retrophin, Inc. (NASDAQ:RTRX)Wall Street Hints and NewsRetrophin, Inc. (NASDAQ:RTRX)'s P/E is 8.46. P/E ratio indicates that a stock's price might be too high or too low when compared to its earnings. There are some investors who might think that a company with a high P/E is overpriced, though sometimes ...and more »
05/22/16 09:46 PMAlpha One Assigns Impact Score Of 0 To Retrophin, Inc. (NASDAQ:RTRX) - RealistInvestor.com - Alpha One Assigns Impact Score Of 0 To Retrophin, Inc. (NASDAQ:RTRX)RealistInvestor.comAlpha One analyzed the various web articles published on Retrophin, Inc. (NASDAQ:RTRX), and thereafter it gave company a daily sentiment score of 0. The entity designs algorithm based assessment to known stock sentiment on stock after considering the ...and more »
05/19/16 03:02 PMRETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Sec -
05/18/16 05:13 PMRETROPHIN INC (RTRX) Jumps 5.02% on May 18 - Equities.com - RETROPHIN INC (RTRX) Jumps 5.02% on May 18Equities.comRETROPHIN INC (RTRX) was among the biggest gainers on the Russell 2000 for Wednesday May 18 as the stock popped 5.02% to $16.33, representing a gain of $0.78 per share. Some 481,831 shares traded hands on 4,172 trades, compared with an ...and more »
05/17/16 08:59 AMTrevena (TRVN) Down on Negative Phase IIb Data on TRV027 - Currently, Trevena has a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Analyst Report), Retrophin, Inc. (RTRX - Snapshot Report) and ANI Pharmaceuticals, Inc. (ANIP - Snapshot Report ...
05/13/16 02:03 PMBet on These 5 Profitable Stocks for Higher Returns -
05/13/16 12:04 PMRETROPHIN, INC. Financials -
05/12/16 05:34 PMRestoring Retrophin's Reputation - Seeking Alpha - Restoring Retrophin's ReputationSeeking AlphaAs Martin Shkreli awaits the possible filing of yet more criminal charges against him and beguiles the hours by going on Tinder dates, his former company Retrophin (NASDAQ:RTRX) appears to be quietly getting on with developing innovative drugs for rare ...
05/12/16 12:13 PMRetrophin, Inc. :RTRX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/11/16 05:38 PMRetrophin Inc (RTRX) Earns “Buy” Rating from Leerink Swann - Washington News Wire - Washington News WireRetrophin Inc (RTRX) Earns “Buy” Rating from Leerink SwannWashington News WireRetrophin Inc (NASDAQ:RTRX)'s stock had its “buy” rating reissued by analysts at Leerink Swann in a research report issued on Wednesday, Market Beat Ratings reports. The analysts wrote, “We believe the quarter signals turnaround on repricing in the ...
05/11/16 05:38 PMLeerink Swann Reaffirms Buy Rating for Retrophin Inc (RTRX) - Washington News Wire - Washington News WireLeerink Swann Reaffirms Buy Rating for Retrophin Inc (RTRX)Washington News WireRetrophin Inc (NASDAQ:RTRX)'s stock had its “buy” rating reaffirmed by investment analysts at Leerink Swann in a research note issued to investors on Wednesday, AnalystRatings.Net reports. The analysts wrote, “We believe the quarter signals turnaround ...Retrophin Inc (RTRX) Earns "Buy" Rating from Leerink SwannWeb Breaking NewsBroker Changes For Retrophin, Inc. (RTRX)Risers & Fallersall 3 news articles »
05/08/16 05:40 PMAfter Last Week What Do Analysts Think Of Retrophin, Inc. (RTRX) - Share Trading News - After Last Week What Do Analysts Think Of Retrophin, Inc. (RTRX)Share Trading News05/30/2014 – Retrophin, Inc. had its “positive” rating reiterated by analysts at ING. The share price of Retrophin, Inc. (RTRX) was down -1.95% during the last trading session, with a day high of 14.76. 638226 shares were traded on Retrophin, Inc.'s ...Were Analysts Bearish Retrophin Inc (NASDAQ:RTRX) This Week?Franklin IndependentZacks Investment Research Upgrades Retrophin Inc (RTRX) to "Strong-Buy"Web Breaking NewsRetrophin Incorporated (NASDAQ:RTRX) Sellers Covered 9.5% of Their ShortsThe Postall 4 news articles »
About Retrophin

Retrophin logoRetrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RTRX
  • CUSIP:
Key Metrics:
  • Previous Close: $17.24
  • 50 Day Moving Average: $16.99
  • 200 Day Moving Average: $16.19
  • P/E Ratio: 8.97
  • P/E Growth: -1.49
  • Market Cap: $632.29M
  • Current Quarter EPS Consensus Estimate: $-0.23 EPS
Additional Links:
Retrophin (NASDAQ:RTRX) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha